Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07288333 | Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia | PHASE2 | RECRUITING | 120 | — | — | Feb 16, 2026 | Aug 1, 2027 | May 26, 2026 | 5 | Bulgaria, United Kingdom |
| Arm | Type | Description |
|---|---|---|
| NBI-1117570: Lower-dose | EXPERIMENTAL | Participants will receive a lower-dose of NBI-1117570. |
| NBI-1117570: Higher-dose | EXPERIMENTAL | Participants will receive a higher-dose of NBI-1117570. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to NBI-1117570. |
| Name | Type | Description |
|---|---|---|
| NBI-1117570 | DRUG | Oral administration |
| Placebo | DRUG | Oral administration |
Key Inclusion Criteria: * 18 to 55 years of age * Primary diagnosis of schizophrenia ≥1 year before screening. * Participant is experiencing an acute exacerbation or relapse of symptoms with onset less than 2 months before screening and currently requires hospitalization. * Participant must have ha...